Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173221 | 0.87 | MAPK1 (0.51) | PARP10PARP15PARP2CYP4F2CYP4A11 | |
| SCHEMBL28707686 | 0.86 | PARP10 (0.62) | PARP10PARP15PARP2CYP4F2CYP4A11 | |
| SCHEMBL457981 | 0.84 | P4HTM (0.56) | PARP10PARP15PARP2CYP4F2CYP4A11 | |
| SCHEMBL31681177 | 0.82 | PARP15 (0.49) | PARP10PARP15PARP2CYP4F2CYP4A11 | |
| SCHEMBL22583269 | 0.77 | PARP10 (0.50) | PARP10PARP15PARP2CYP4F2CYP4A11 | |
| SCHEMBL20812681 | 0.76 | CNR2 (0.60) | MCHR1 | |
| SCHEMBL20812228 | 0.75 | CNR2 (0.61) | PARP10PARP15PARP2CYP4F2CYP4A11 | |
| Nitrous Acid SCHEMBL28713860 | 0.74 | PARP10 (0.48) | PARP10PARP15PARP2CYP4F2CYP4A11 | |
| SCHEMBL27951296 | 0.72 | ACACB (0.52) | PARP10PARP15PARP2CYP4F2CYP4A11 | |
| SCHEMBL19405761 | 0.72 | ACACA (0.53) | P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729071-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729071-B2 | Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120183563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | disclosed |
| US-20120183563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183563-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | BACE1, BACE2, APP | PARP10 1996/4885PARP15 755/4885PARP2 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.